Review
Version 1
Preserved in Portico This version is not peer-reviewed
Shugoshin: From a Perspective of Clinical Disorders
Version 1
: Received: 24 March 2021 / Approved: 25 March 2021 / Online: 25 March 2021 (15:31:59 CET)
A peer-reviewed article of this Preprint also exists.
Kumar, R.; Agarwal, M. Shugoshin: From the Perspective of Clinical Disorders. BioChem 2021, 1, 51–59, doi:10.3390/biochem1020006. Kumar, R.; Agarwal, M. Shugoshin: From the Perspective of Clinical Disorders. BioChem 2021, 1, 51–59, doi:10.3390/biochem1020006.
Abstract
Proper and timely segregation of cellular genome is an important and a prime requirement of all cell division programmes. Mis-segregation of chromosomes and resulting aneuploidy leads to several clinical consequences. Over the years, shugoshin emerges as a key protein factor involved in the segregation of genetic material in dividing cells. Deletion or altered level of shugoshin is reported in several human malignancies, as a result, shugoshin now emerges as an important tumour associated gene and a possible target for cancer therapy. Apart from the role in cancer, recent studies also showed the involvement of shugoshin in several other clinical disorders. Through this review, we tried to highlight the clinical relevance of shugoshin.
Keywords
Shugoshin; tumor suppressor; cancer; oncogene; tumour associated gene
Subject
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
